Poison pills remain as Lilly shareholder vote falls short
The proposal garnered support from the owners of 62 percent of Eli Lilly’s outstanding shares. To pass, the proposal needed approval from the owners of 80 percent of Lilly’s shares.
Home » Search
Search Results
4,410 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Lilly CEO says cost-cutting won’t solve sales losses
Eli Lilly and Co., facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting to overcome the revenue loss, CEO John Lechleiter said Thursday in Boston at the annual meeting of the Pharmaceutical Research and Manufacturers of America.
RIVERA: Dreaming up charter school possibilities
Imagine high school graduates from the Eli Lilly or the Cook Pharma Charter School of Chemistry.
New Lilly drug has small sales potential
Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
Lilly wins FDA approval for Alzheimer’s imaging agent
The agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
New data brightens Indy area’s jobs picture
Bureau of Labor Statistics revises numbers, but region is still 30,000 jobs short of pre-recession peak.
Purchase of city water utility lifts Citizens Energy’s profits
The $1.9 billion sale of the city’s water and sewer utilities was a profit gusher last year for buyer Citizens Energy Group—at least on paper. Dwarfing the returns of its gas, thermal and other divisions, the newly renamed Citizens Water turned a profit of $53.4 million.
Promised tariff cuts could spur Indiana exports to China
Indiana logistics firms and their manufacturing clients could gain new export opportunities to China if the country follows through on plans to reduce taxes on imported goods.
Company news
Researchers at the Indiana University School of Medicine may have found a way to predict who will develop Type 1 diabetes, according to a study published March 22 in the journal Diabetes. Dr. Raghu Mirmira and Sarah Tersey, both professors in the pediatric department of the IU medical school, reported that they had been able to identify problems in insulin-producing cells in mice before the mice actually developed symptoms of diabetes. They were also able to identify a protein in the mice that rises in level as insulin-producing cells become dysfunctional. Screening for that protein in blood tests could identify patients in the process of developing diabetes. Type 1 diabetes, also known as juvenile diabetes, occurs when the body’s immune system attacks insulin-producing cells in the pancreas.
Purdue University’s Emerging Innovations Fund invested $80,000 in Spensa Technologies Inc. and another $20,000 in Tymora Analytical Operations LLC. Both companies are based in the Purdue Research Park in West Lafayette. Spensa Technologies is commercializing the Z-Trap, which detects target insects captured by the trap and sends the data wirelessly to a farmer’s mobile phone or computer. Knowing the types of pests can help farmers select the correct pesticide and the right amount to apply. Tymora Analytical incorporates nanotechnology in laboratory products designed to make cancer research and drug discovery more efficient and effective.
European regulators approved an expanded use for the diabetes treatment Byetta developed by drugmakers Amylin Pharmaceuticals Inc. and Eli Lilly and Co., according to the Associated Press. The companies said Friday they received approval for Byetta to be used with or without common treatments like metformin and Actos to treat adult Type 2 diabetes patients who have not been able to control their blood sugar levels with just insulin. The U.S. Food and Drug Administration approved the same expanded use last fall. Byetta, or exenatide, is a twice-a-day injection. It was first approved in Europe in 2006. Amylin and Lilly announced in November that they are ending their collaboration on Byetta and its successor, Bydureon, which is designed to be taken once per week. The two companies have already ended their partnership in the United States, and Amylin will take over marketing of Byetta outside the U.S. by the end of 2013.
40-foot molecule sculpture going up along I-70
An Interstate 70 ramp in downtown Indianapolis is expected to be shut down for several days so that a 40-foot metal sculpture of a molecule can be built.
Lilly receives Europe’s OK for new Byetta use
European regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
Lilly to focus on cancer, diabetes in China, CEO says
Indianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years, focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
Lilly gets good news on insulin
Decision by industry giant Pfizer Inc. to abandon its generic insulin project is good news for Eli Lilly and Co.
PROXY CORNER: Eli Lilly and Co.
Indianapolis-based Eli Lilly and Co discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
What’s New: Grateful Pet
Melissa Kelly and Zach Pierson, who opened delivery service Grateful Pet LLC in July and are bootstrapping the business through Kelly’s day job.
Q&A
Jan Lundberg, Eli Lilly and Co.’s executive vice president of science and technology, discussed the Indianapolis-based drugmaker’s latest efforts to improve its research and development efforts.
CEO helps Conner Prairie educate by creating ‘social experience’
Conner Prairie President and CEO Ellen Rosenthal has brought to the Fishers museum her passion for creating great visitor experiences.